Durvalumab (D) +/- Tremelimumab (T) plus Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON
JOURNAL OF THORACIC ONCOLOGY(2022)
关键词
Durvalumab, Tremelimumab, POSEIDON
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要